Jun 17, 2024 8:05am EDT Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Jun 05, 2024 8:05am EDT Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
May 20, 2024 8:01am EDT Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
May 15, 2024 8:00pm EDT Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
May 15, 2024 8:45am EDT Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
May 09, 2024 8:00am EDT Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Apr 18, 2024 4:30pm EDT Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Apr 03, 2024 8:05am EDT Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Mar 27, 2024 4:15pm EDT Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Mar 07, 2024 8:30am EST Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders